Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interleukin-2 therapy of Autoimmunity in Diabetes (ITAD)
2017-002126-20Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- Feb 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Ultra-low dose aldesleukin with Placebo (2 arms). Primary endpoint: Change in endogenous beta-cell function (DBS C-peptide slope). Status: unknown.
02
Drugs
aldesleukin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2017-002126-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002126-20.